|
CA3090315A1
|
|
Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
|
|
US2019336492A1
|
|
Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth
|
|
US2019240188A1
|
|
Small molecules against cancer
|
|
US2018221393A1
|
|
Cxcr4 binding agents for treatment of diseases
|
|
US2018161366A1
|
|
Methods of obtaining mononuclear blood cells and uses thereof
|
|
US2017226157A1
|
|
Compositions and methods for the treatment of ocular diseases
|
|
CN106029084A
|
|
Methods of treating acute myeloid leukemia with an FLT3 mutation
|
|
EP2841084A1
|
|
Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
|
|
WO2012095849A1
|
|
Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
|
|
BRPI1009716A2
|
|
peptide bonds of chemokine, capable of inhibiting the course of autoimmunity, inflammation and cancer
|
|
KR20120037463A
|
|
Peptide therapy for increasing platelet levels
|
|
WO2008075369A2
|
|
T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
|
|
US2006264378A1
|
|
Cxcr4 antagonist and use thereof
|
|
AU2003209636A8
|
|
Novel chemokine binding peptides capable of modulating the biological activity of chemokines
|
